 |  |
| ABX | ||
| 2,542.904 | ||
| 33.3600 | 0.0133% | |
| BISNIS-27 | ||
| 552.880 | ||
| 2.2060 | 0.0040% | |
| DBX | ||
| 4,209.768 | ||
| 39.8680 | 0.0096% | |
| ECONOMIC30 | ||
| 116.183 | ||
| 0.2570 | 0.0022% | |
| ESGQKEHATI | ||
| 127.761 | ||
| 0.3880 | 0.0030% | |
| ESGSKEHATI | ||
| 128.385 | ||
| 0.5830 | 0.0046% | |
| I-GRADE | ||
| 232.622 | ||
| 1.4310 | 0.0062% | |
| AUDRP | ||
| 11,081.530 | ||
| 32.5800 | 0.2949% | |
| EURRP | ||
| 19,437.130 | ||
| 59.9500 | 0.3094% | |
| JPYRP | ||
| 107.551 | ||
| 0.4057 | 0.3786% | |
| SINRP | ||
| 12,874.570 | ||
| 38.1400 | 0.2971% | |
| USDRP | ||
| 16,679.000 | ||
| 34.0000 | 0.2043% | |
Kandidat obat oral untuk pasien COVID-19 bertambah dengan kehadiran pil antivirus Paxlovid. Berdasarkan hasil sementara uji klinis fase II/III, Paxlovid menunjukkan hasil yang baik sehingga segera diajukan untuk mendapatkan izin penggunaan darurat.
